Please ensure Javascript is enabled for purposes of website accessibility

Why Akorn, Inc.'s Stock Is Up Big Today

By Brian Feroldi – Apr 27, 2018 at 4:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drama continues.

What happened

In response to receiving some positive commentary from a Wall Street analyst, shares of Akorn, Inc. (AKRX), a maker of specialty generic pharmaceutical products, rose as much as 11% in afternoon trading today. As of 3:15 p.m. EDT, shares were up about 7%. 

So what 

Shareholders can thank RBC Capital analyst Randall Stanicky for today's price action. Stanicky published a bullish research note today related to Akorn's potential takeover by Fresenius Medical Care AG & Co. (FMS 1.28%) that has traders feeling excited.

If you haven't been following this story closely, Fresenius signed a deal to acquire Akorn for $34 per share last year. However, Fresenius recently decided to terminate the deal after it performed some due diligence on the company and came away displeased.

Despite the setback, Akorn's management team remains adamant that Fresenius did not unearth any evidence that could allow it to terminate the signed agreement and is fighting hard to ensure that the merger closes.

Two people looking at legal documents

Image source: Getty Images.

With shares of Akorn trading in the low teens, it is obvious that Wall Street has lost all faith that this deal will ever get done. However, Stanicky looked at the publicly available court documents from this legal battle and concluded that he still sees "a path for the deal to close."

That renewed optimism is fueling today's rally.

Now what

It is impossible to know how this legal dispute will end, so Akorn's shareholders need to make sure that they want to own the company no matter the outcome. Personally, I find it troubling that Fresenius took a hard look at Akorn's business and is now doing whatever it can to stop the deal from happening. For that reason, I plan on keeping this stock far away from my portfolio.

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Akorn, Inc. Stock Quote
Akorn, Inc.
AKRX
Fresenius Medical Care AG & Co. KGaA Stock Quote
Fresenius Medical Care AG & Co. KGaA
FMS
$14.22 (1.28%) $0.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.